Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

SLS
SELLAS Life Sciences Group, Inc. Common Stock
stock NASDAQ

Market Open
Aug 11, 2026 10:53:14 AM EDT
10.97USD-0.544%(-0.06)1,202,611
9.35Bid   10.97Ask   1.62Spread
Pre-market
Aug 11, 2026 9:29:30 AM EDT
11.31USD+2.539%(+0.28)22,563
After-hours
Aug 10, 2026 4:58:30 PM EDT
11.09USD+0.549%(+0.06)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
08:05PM EST  SELLAS Life Sciences Announced IND Acceptance for First Clinical Trial of GPS in China   Benzinga
Jan 24, 2022
11:57AM EST  Shares of SELLAS Life Sciences Group, Inc. (SLS) slipped nearly 14% on Monday morning despite no stock-related news from the company to hurt the shares.   RTTNews
Jan 18, 2022
06:00AM EST  Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (Solaris or the Company) is pleased to announce a significant new discovery in maiden drilling of the Warintza South target at its Warintza Project (Warintza or the Project) in southeastern Ecuador.   GlobeNewswire Inc
Jan 5, 2022
08:30AM EST  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that John T. Burns has been promoted within the Company to Senior Vice President, Finance, and Chief Accounting Officer.   GlobeNewswire Inc
Dec 14, 2021
07:31AM EST  Solaris Extends Warintza Central to South, Southeast and Still Open; Maiden   PR Newswire
Dec 6, 2021
07:01AM EST  Solaris Announces Proposed Spin-Out of Non-Core Assets to Create Solaris   PR Newswire
Nov 23, 2021
08:33AM EST  SELLAS Life Sciences Reports Final Court Approval Of Settlement Of Derivative Litigation   Benzinga
08:30AM EST  SELLAS Life Sciences Announces Final Court Approval of Settlement   GlobeNewswire Inc
Nov 15, 2021
07:31AM EST  Solaris Reports 920m of 0.62% CuEq and 1,080m of 0.41% CuEq; Warintza Central   PR Newswire
Nov 12, 2021
08:50AM EST  SELLAS Life Sciences Q3 EPS $(0.45) Up From $(0.53) YoY   Benzinga
08:45AM EST  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.   GlobeNewswire Inc
Nov 1, 2021
07:31AM EDT  Solaris Commences Maiden Drilling at Warintza South; Updated Geophysics and   PR Newswire
Oct 25, 2021
07:31AM EDT  Solaris Extends Warintza Central to 1,350m Strike Length to Overlap Warintza   PR Newswire
Oct 12, 2021
07:31AM EDT  Solaris Reports 1,000m of 0.81% CuEq From Surface; Broadens Width of Warintza   PR Newswire
Oct 7, 2021
09:14AM EDT  SELLAS Life Sciences Group, Inc.(NASDAQ: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences:   GlobeNewswire Inc
Sep 27, 2021
07:31AM EDT  Solaris Expands Warintza East Discovery; Ongoing Drilling Targeting High Grade   PR Newswire
Sep 23, 2021
04:10PM EDT  SELLAS Life Sciences Reports Settlement Of Derivative Litigation   Benzinga
04:05PM EDT  SELLAS Life Sciences Announces Settlement of Derivative Litigation   GlobeNewswire Inc
Sep 14, 2021
08:30AM EDT  SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global   GlobeNewswire Inc
Sep 7, 2021
07:31AM EDT  Solaris Reports 1,184m of 0.68% CuEq From Surface in Expansion of Warintza   PR Newswire
Aug 30, 2021
07:02AM EDT  Solaris Appoints Sunny Lowe as Chief Financial Officer   PR Newswire
Aug 24, 2021
09:00PM EDT  Solaris Updates Technical Disclosure   PR Newswire
Aug 12, 2021
04:41PM EDT  SELLAS Life Sciences Q2 EPS $(0.30) Up From $(0.66) YoY   Benzinga
Jul 28, 2021
08:30AM EDT  Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee   GlobeNewswire Inc
Jul 23, 2021
06:06PM EDT  Solaris Files La Verde Technical Report   PR Newswire
Jul 21, 2021
07:24AM EDT  Cantor Fitzgerald Initiates Coverage On SELLAS Life Sciences Gr with Overweight Rating, Announces Price Target of $18   Benzinga
Jul 20, 2021
11:39AM EDT  IIROC Trade Resumption - SLS   PR Newswire
11:29AM EDT  Solaris Announces Significant New Discovery at Warintza East   PR Newswire
09:37AM EDT  IIROC Trading Halt - SLS   PR Newswire
Jul 7, 2021
04:52PM EDT  SELLAS Life Sciences Group 8K Shows Co. Had $32M In Cash, Cash Equivalents, 15.8M Shares Of Common Stock Outstanding; Says Including 421K Shares Sold To Co.'s Controlled Equity Offering Sales Agreement With Cantor Fitzgerald, Priced At $13.15/Share   Benzinga
07:01AM EDT  Solaris Reports 1,000m of 0.60% CuEq From Surface, Extending Warintza Central   PR Newswire
Jun 30, 2021
11:24AM EDT  Sellas Life Sciences Reports Encouraging Immune Response From GPS Combo Trial In Ovarian Cancer   Benzinga
08:56AM EDT  SELLAS Reports Updated Clinical Data From Phase 1/2 Study Of Galinpepimut-S Combined With Keytruda Showing 100% Of Patients Alive And 45.5 Percent Continuing Investigational Therapy As Of The Latest Follow-Up   Benzinga
08:55AM EDT  Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up   GlobeNewswire Inc
Jun 29, 2021
04:39PM EDT  Solaris Announces Results of Annual General Meeting of Shareholders   PR Newswire
Jun 24, 2021
08:34AM EDT  SELLAS Reports Updated Clinical Data From Ongoing Mesothelioma Study Of Galinpepimut-S (GPS) Combined With Opdivo   Benzinga
08:30AM EDT  Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeks   GlobeNewswire Inc
Jun 22, 2021
09:19AM EDT  SELLAS Life Sciences To Join Russell Microcap Index, Effective Jun. 28   Benzinga
09:06AM EDT  SELLAS Life Sciences Announces Inclusion in Russell   GlobeNewswire Inc
Jun 21, 2021
10:15AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021   Benzinga
Jun 14, 2021
07:01AM EDT  Solaris Commences Maiden Drilling at Warintza East; Major Porphyry Target   PR Newswire
May 27, 2021
08:33AM EDT  SELLAS Life Sciences Reports US Patent & Trademark Office Decision To Grant New Patent For Galinpepimut-S In Combo With Checkpoint Inhibitor Therapies   Benzinga
08:30AM EDT  SELLAS Life Sciences Announces USPTO Decision to Grant New Patent   GlobeNewswire Inc
May 26, 2021
07:01AM EDT  Solaris Reports 1,029m of 0.73% CuEq From Surface, Expands Warintza Central to   PR Newswire
May 13, 2021
05:11PM EDT  SELLAS Life Sciences Q1 EPS $(0.16) Up From $(0.66) YoY   Benzinga
04:25PM EDT  Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) in Greater China   GlobeNewswire Inc
May 12, 2021
08:17PM EDT  Solaris Announces Inclusion in the MSCI Canada Small Cap Index   PR Newswire
May 11, 2021
07:30AM EDT  SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.   GlobeNewswire Inc
Apr 19, 2021
07:02AM EDT  Solaris Reports 800m of 0.83% CuEq From Surface including 370m of 0.94% CuEq;   PR Newswire
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
Mar 23, 2021
04:23PM EDT  SELLAS Life Sciences FY20 Licensing Revenue $1.9M   Benzinga
04:21PM EDT  Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercialization of Galinpepimut-S in China; Additional $1 Million Milestone Triggered in February 2021   GlobeNewswire Inc
Mar 22, 2021
06:01AM EDT  Solaris Reports 922m of 0.94% CuEq From Surface in Continued Expansion of   PR Newswire
Mar 16, 2021
07:31AM EDT  Solaris Appoints Kevin Thomson to Board of Directors   PR Newswire
Mar 11, 2021
08:30AM EST  SELLAS Life Sciences to Participate in the M Vest and Maxim Group   GlobeNewswire Inc
Feb 25, 2021
01:44PM EST  Toronto Stock Exchange, Solaris Resources, C-Suite at The Open   PR Newswire
Feb 22, 2021
06:31AM EST  Solaris Reports 600m of 1.0% CuEq and 462m of 1.0% CuEq From Surface, Continued   PR Newswire
Feb 16, 2021
09:16AM EST  IIROC Trade Resumption - SLS   PR Newswire
09:04AM EST  Solaris Announces New Discovery at Warintza West, Geophysics Reveal More   PR Newswire
08:36AM EST  IIROC Trading Halt - SLS   PR Newswire
Feb 5, 2021
07:31AM EST  Solaris to Commence Trading on Toronto Stock Exchange February 9   PR Newswire
Feb 3, 2021
11:21AM EST  Mid-Morning Market Update: Markets Mixed; Alphabet Beats Q4 Expectations   Benzinga
Feb 1, 2021
07:31AM EST  Solaris Secures Conditional Approval to List on the Toronto Stock Exchange   PR Newswire
Jan 14, 2021
08:40AM EST  SELLAS Life Sciences Highlights 2020 Business And Clinical Progress And 2021 Milestones   Benzinga
08:30AM EST  - Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe -   GlobeNewswire Inc
07:31AM EST  Solaris Reports 1,067m of 0.60% CuEq From Surface, Expands Limits of Warintza   PR Newswire
Dec 21, 2020
08:30AM EST  - Early Data from Study of GPS in Combination with Keytruda in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeksand 100% Progression Free Survival at 6 Weeks -   GlobeNewswire Inc
Dec 17, 2020
08:30AM EST  - Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing -   GlobeNewswire Inc
Dec 14, 2020
11:11AM EST  IIROC Trading Resumption - SLS   PR Newswire
10:14AM EST  Mid-Morning Market Update: Markets Open Higher; FDA Authorizes Pfizer-BioNTech Covid-19 Vaccine   Benzinga
09:37AM EST  Learning Caution In A Volatile December   Benzinga
08:20AM EST  IIROC Trading Halt - SLS   PR Newswire
12:24AM EST  SELLAS Announces Pricing Of Registered Direct Offering At $7/Shr   RTTNews
Dec 13, 2020
08:10PM EST  SELLAS Announces Pricing of $16.2 Million Registered Direct Offering   GlobeNewswire Inc
Dec 11, 2020
02:30PM EST  Mid-Afternoon Market Update: Dow Turns Higher; Nabriva Therapeutics Shares Slide   Benzinga
12:14PM EST  Mid-Day Market Update: Nasdaq Tumbles 100 Points; Sonoma Pharmaceuticals Shares Surge   Benzinga
11:50AM EST  Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment   GlobeNewswire Inc
10:19AM EST  Mid-Morning Market Update: Markets Edge Lower; Pfizer Coronavirus Vaccine Receives FDA Panel's Nod   Benzinga
08:34AM EST  UPDATE: SELLAS Says 'Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment'   Benzinga
08:34AM EST  SELLAS Reports Follow-Up Data From Randomized Phase 2 VADIS Trial Of Nelipepimut-S In Women With Ductal Carcinoma In-Situ Of The Breast   Benzinga
08:33AM EST  UPDATE: SELLAS Says 'Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094'   Benzinga
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
10:34AM EST  Shares of biopharmaceutical company SELLAS Life Sciences Group, Inc. (SLS) are extending strong gains from the previous sessions and rising more than 14 percent or $0.90 in Thursday's morning trade at $7.29, after hitting a new 52-week high of $9.29.   RTTNews
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 7, 2020
08:30AM EST  - SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 MillionNear-term Milestones, plus Tiered Royalties-   GlobeNewswire Inc
Nov 23, 2020
12:55PM EST  IIROC Trading Resumption - SLS   PR Newswire
10:47AM EST  IIROC Trading Halt - SLS   PR Newswire
Nov 13, 2020
04:35PM EST  SELLAS Life Sciences Q3 EPS $(0.53) Up From $(2.68) YoY   Benzinga
04:32PM EST  - ReceivedIMPDApproval to CommenceEnrollment in France for PivotalPhase 3Studyof Galinpepimut-S in Acute Myeloid Leukemia Patients-   GlobeNewswire Inc
Nov 9, 2020
09:30AM EST  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Sep 28, 2020
10:40AM EDT  IIROC Trading Resumption - SLS   PR Newswire
09:27AM EDT  IIROC Trading Halt - SLS   PR Newswire
Sep 17, 2020
07:31AM EDT  Solaris Announces New U.S. Listing on OTCQB Venture Market Under Symbol "SLSSF"   PR Newswire
Sep 9, 2020
08:31AM EDT  SELLAS Reports Receives Investigational Medicinal Product Dossier Approval From French Regulatory Authority, Agence Nationale de Scurit du Mdicament et des Produits de Sant, To Advance Pivotal Phase 3 REGAL Study   Benzinga
08:30AM EDT  SELLAS Receives IMPD Approval from the French Regulatory Authority   GlobeNewswire Inc
Aug 13, 2020
04:34PM EDT  SELLAS Life Sciences Q2 EPS $(0.66) Down From $(0.13) YoY   Benzinga
04:30PM EDT  - Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market-- Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with multiple data readouts expected in next 18 months -   GlobeNewswire Inc
Aug 10, 2020
12:24PM EDT  IIROC Trading Resumption - SLS   PR Newswire
09:24AM EDT  IIROC Trading Halt - SLS   PR Newswire
Jul 31, 2020
01:32PM EDT  SELLAS Life Sciences Announces $9.2M Private Placement Priced At-The-Market   Benzinga
01:30PM EDT  SELLAS Life Sciences Announces $9.2 Million Private Placement   GlobeNewswire Inc
Jul 20, 2020
10:00AM EDT  C-Suite At The Open: Daniel Earle, President & CEO, Solaris Resources Inc.   PR Newswire
Jul 14, 2020
11:00AM EDT  Solaris Resources Inc. Virtually Opens The Market   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC